SEC Form 4	ŀ
------------	---

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

1. Name and Address of Reporting Person* GOLDMAN SACHS GROUP INC				r Name <b>and</b> Ticker iosystems, In	• •			tionship of Reportin all applicable) Director	• • • •		ssuer Owner
(Last) 200 WEST STR	(First) REET	(Middle)	3. Date 06/19/	of Earliest Transac 2015	tion (Month/D	ay/Year)		Officer (give title below)		Other below)	(specify
(Street) NEW YORK (City)	NY (State)	10282 (Zip)	4. If Am	endment, Date of C	Driginal Filed (	Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Form filed by One Form filed by Mor Person	e Reporti	ng Perso	on
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1. Title of Security	(Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any	3. Transaction Code (Instr.	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)		5. Amount of Securities Beneficially	6. Owne Form: D (D) or In	Direct	7. Nature of Indirect Beneficial

	(Month/Day/Year)	Execution Date, if any (Month/Day/Year)			Disposed Of (D) (Instr. 3, 4 and 5)				Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)	
Table II. Devinating Converting Associated Dispersed of an Deveficially Owned											

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Number		6. Date Exercisable and Expiration Date (Month/Day/Year)		le and 7. Title and Amount of Securities		Ind Amount 8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$18.59	06/19/2015		A		17,647		(2)	(2)	Common Stock	17,647	\$0	17,647	Ι	See footnotes <sup>(1)(2)</sup>


## 1. Name and Address of Reporting Person\* GOLDMAN SACHS GROUP INC

(Last)	(First)	(Middle)									
200 WEST STREET											
(Street)											
NEW YORK	NY	10282									
(City)	(State)	(Zip)									
1. Name and Address of Reporting Person*											
GOLDMAN SACHS & CO											
(Last)	(First)	(Middle)									
200 WEST STREET											
(Street)											
NEW YORK	NY	10282									
(City)	(State)	(Zip)									

## Explanation of Responses:

1. This statement is being filed by The Goldman Sachs Group, Inc. ("GS Group") and Goldman, Sachs & Co. ("Goldman Sachs," and together with GS Group, the "Reporting Persons"). Goldman Sachs is a wholly-owned subsidiary of GS Group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.

2. The options to purchase 17,647 shares of Common Stock, par value \$0.001 per share (the "Common Stock") of T2 Biosystems, Inc. (the "Company") were granted to Thomas J. Carella, a managing director of Goldman Sachs, in his capacity as a director of the Company pursuant to the T2 Biosystems, Inc. Non-Employee Director Compensation Program under the T2 Biosystems, Inc. 2014 Incentive Award Plan. The grant of 17,647 options will vest and become exercisable in twelve substantially equal monthly installments following the grant date, subject to continued board service through each such date. Mr. Carella has an understanding with GS Group pursuant to which such options are held for the benefit of GS Group.



0<u>6/29/2015</u>

/s/ Yvette Kosic, Attorney-in- 06/29/2015

\*\* Signature of Reporting Person Date

fact

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.